Dyne Therapeutics (NASDAQ:DYN) Now Covered by Raymond James

Raymond James assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report issued on Wednesday, MarketBeat.com reports. The firm set an “outperform” rating and a $37.00 price target on the stock. Raymond James’ target price points to a potential upside of 155.88% from the company’s current price.

Other equities analysts have also issued research reports about the stock. BMO Capital Markets began coverage on shares of Dyne Therapeutics in a report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Friday, May 9th. Oppenheimer started coverage on Dyne Therapeutics in a research note on Monday, June 2nd. They set an “outperform” rating and a $34.00 price target for the company. HC Wainwright reduced their target price on shares of Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Finally, Evercore ISI assumed coverage on Dyne Therapeutics in a report on Thursday, May 29th. They issued an “outperform” rating and a $46.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $44.93.

Dyne Therapeutics Stock Down 0.8%

NASDAQ DYN opened at $14.46 on Wednesday. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -4.06 and a beta of 1.17. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $47.45. The business’s fifty day moving average is $11.04 and its 200 day moving average is $15.33.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). On average, research analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd grew its holdings in Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock valued at $32,000 after buying an additional 2,446 shares in the last quarter. Quarry LP purchased a new position in shares of Dyne Therapeutics during the 1st quarter valued at about $47,000. GF Fund Management CO. LTD. purchased a new position in shares of Dyne Therapeutics during the fourth quarter worth approximately $50,000. E Fund Management Co. Ltd. raised its position in Dyne Therapeutics by 16.2% in the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company’s stock worth $144,000 after purchasing an additional 1,923 shares during the period. Finally, Optimize Financial Inc purchased a new position in shares of Dyne Therapeutics in the first quarter worth about $154,000. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.